Redeye sees a quarter developing per our expectations, and we make no estimate revisions. We continue to see upside potential to our base case, but we point to the extreme share price development in the past six months and argue that shorter-term sell-offs pose a risk to the stock.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Integrum Q3 - In line and no estimate changes

© Modular Finance, source Nordic Press Releases